![]() ZAI Lab Zai Lab is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for cancer, autoimmune and infectious diseases. | ![]() Amoy Diagnostics Amoy Diagnostics (AmoyDx, 厦门艾德生物医药科技股份有限公司) is a company that provides molecular diagnostic products and services for oncology precision medicine. | BGI Genomics BGI Genomics (华大基因, 深圳华大基因股份有限公司) is a company offering genomic sequencing and proteomic services. | ![]() Berry Genomics Berry Genomics (贝瑞基因) is a biotechnology company that develops sequencing-based integrated solutions for life sciences and clinical applications, primarily in genetic testing and oncology testing. | ![]() Shanghai Junshi Biosciences Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases. | |
Founding Date | Founding Date 2014 | Founding Date 2008 | Founding Date 1999 | Founding Date 2010 | Founding Date 2012 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations CN HQ Suzhou, CN Hong Kong, HK Taipei, TW Cambridge, US Menlo Park, US | Locations Xiamen, CN HQ Singapore, SG | Locations Shenzhen, CN HQ Brisbane, AU Copenhagen, DK Addis Ababa, ET Hong Kong, HK Budapest, HU Kobe, JP see more | Locations CN HQ | Locations Shanghai, CN HQ |
Employees | Employees 1,869 | Employees 1,144 | Employees 3,702 | Employees 1,4023% decrease | Employees 2,568 |
Valuation ($) | Valuation ($) 3.2 b | Valuation ($) 1.3 b | Valuation ($) 2.7 b | Valuation ($) 460.5 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $399m (FY, 2024) | Revenue (est.) ¥1.1b (FY, 2024) | Revenue (est.) ¥3.8b (FY, 2024) | Revenue (est.) ¥1.1b (FY, 2023) | Revenue (est.) ¥1.9b (FY, 2024) |
Cost of goods | Cost of goods $147.1m (FY, 2024) | Cost of goods ¥169.1m (FY, 2024) | Cost of goods ¥2.3b (FY, 2024) | Cost of goods ¥636.2m (FY, 2023) | Cost of goods ¥410.7m (FY, 2024) |
Gross profit | Gross profit $251.9m (FY, 2024) | Gross profit ¥934.8m (FY, 2024) | Gross profit ¥1.6b (FY, 2024) | Gross profit ¥506.6m (FY, 2023) | Gross profit ¥1.5b (FY, 2024) |
Net income | Net income ($257.1m) (FY, 2024) | Net income ¥254.9m (FY, 2024) | Net income (¥912.1m) (FY, 2024) | Net income (¥425.3m) (FY, 2023) | Net income (¥1.4b) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 985m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 145.7m | Total funding raised N/A |
Amoy Diagnostics (AmoyDx, 厦门艾德生物医药科技股份有限公司) is a company that provides molecular diagnostic products and services for oncology precision medicine.
View companyBGI Genomics (华大基因, 深圳华大基因股份有限公司) is a company offering genomic sequencing and proteomic services.
View companyBerry Genomics (贝瑞基因) is a biotechnology company that develops sequencing-based integrated solutions for life sciences and clinical applications, primarily in genetic testing and oncology testing.
View companyShanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.
View company